Diffuse large B-cell lymphoma in a hepatitis C virus-infected patient presenting with lactic acidosis and hypoglycemia

American Journal of the Medical Sciences

Volumn 339, Issue 2, 2010, Pages 202-204

  Keller, Brian C ^a   Nussensveig, Daniel ^b   Dowell, Jonathan E ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b North Texas Healthcare System   (United States)

Author keywords

Hepatitis C; Lactic acidosis; Lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISONE; RASBURICASE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; LABORATORY TEST; LACTIC ACIDOSIS; LARGE CELL LYMPHOMA; LIVER BIOPSY; MALE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; SIGMOIDOSCOPY; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

EID: 77049088050     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181c3fdeb     Document Type: Article

References (16)

1. Sillos EM, Shenep JL, Burghen GA, et al. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer 2001;92:2237-2246
2. Friedenberg AS, Brandoff DE, Schiffman FJ. Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review. Medicine (Baltimore) 2007;86:225-232
3. Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006;131:1879-1886 (Pubitemid 44958516)
4. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451-458
5. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010-2017
6. Cocco P, Piras G, Monne M, et al. Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol 2008;87:474-483
7. Morton LM, Engels EA, Holford TR, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev 2004; 13:425-430
8. Schollkopf C, Smedby KE, Hjalgrim H, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122:1885-1890
9. Landau DA, Saadoun D, Calabrese LH, et al. The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 2007;6:581-587
10. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006;24:953-960
11. Park BB, Kim JS, Lee YY, et al. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49:88-94.
12. Alisi A, Giannini C, Spaziani A, et al. Hepatitis C virus core protein enhances B lymphocyte proliferation. Dig Liver Dis 2007;39(suppl 1): S72-5.
13. Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007;13: 2467-2478
14. Shiratori S, Tsutsumi Y, Kawamura T, et al. HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution. Int J Hematol 2008;87:298-302.
15. Iannitto E, Ammatuna E, Tripodo C, et al. Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha interferon treatment. Hematol J 2004;5:530-533
16. Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120:1034-1041